Cellebrite DI (CLBT) to Announce Earnings on Thursday

Cellebrite DI (NASDAQ:CLBT) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Cellebrite DI to announce earnings of $0.0616 per share and revenue of $131.8740 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $15.90 on Tuesday. Cellebrite DI has a fifty-two week low of $11.02 and a fifty-two week high of $19.98. The company has a 50 day moving average price of $14.55 and a 200 day moving average price of $14.09. The stock has a market capitalization of $3.97 billion, a P/E ratio of 56.79, a PEG ratio of 1.98 and a beta of 1.18.

Analyst Upgrades and Downgrades

CLBT has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. DA Davidson raised their price objective on Cellebrite DI from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Needham & Company LLC cut their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.80.

Insider Buying and Selling

In related news, CEO Thomas E. Hogan sold 103,188 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the completion of the transaction, the chief executive officer owned 590,777 shares of the company’s stock, valued at approximately $9,310,645.52. This represents a 14.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David Barter sold 41,734 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 157,580 shares of company stock worth $2,471,488 in the last ninety days. Insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently modified their holdings of CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Cellebrite DI by 16.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock worth $3,362,000 after acquiring an additional 24,881 shares during the last quarter. Geode Capital Management LLC grew its stake in Cellebrite DI by 16.2% during the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock valued at $5,029,000 after purchasing an additional 43,898 shares in the last quarter. Invesco Ltd. increased its holdings in Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after purchasing an additional 209,473 shares during the last quarter. First Trust Advisors LP acquired a new position in shares of Cellebrite DI in the 2nd quarter valued at approximately $341,000. Finally, Marshall Wace LLP purchased a new position in shares of Cellebrite DI during the 2nd quarter valued at approximately $4,472,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.